A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Children and Young Adults With Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) Followed by Long-term Open-label Treatment

Trial Profile

A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Children and Young Adults With Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) Followed by Long-term Open-label Treatment

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jul 2018

At a glance

  • Drugs Ganaxolone (Primary)
  • Indications Epilepsy
  • Focus Registrational; Therapeutic Use
  • Acronyms MARIGOLD
  • Sponsors Marinus Pharmaceuticals
  • Most Recent Events

    • 19 Jun 2018 Status changed from planning to recruiting, according to a Marinus Pharmaceuticals media release.
    • 12 Mar 2018 New trial record
    • 06 Mar 2018 According to Marinus Pharmaceuticals media release, study is expected to start in mid 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top